Compare
Lexaria Bioscience Corp. vs BioXcel Therapeutics, Inc. vs Onconetix, Inc. vs Vaccinex, Inc.
| Latest fiscal year | Lexaria Bioscience Corp. LEXX | BioXcel Therapeutics, Inc. BTAIQ | Onconetix, Inc. ONCO | Vaccinex, Inc. VCNXLast annual report: year ended 2024-12-31 |
|---|---|---|---|---|
| Year ended | 2025-08-31 | 2025-12-31 | 2025-12-31 | 2024-12-31 |
| Revenue | $705.9K | $642.0K | $815.4K | $601.0K |
| Revenue growth (YoY) | +52.0% | -71.7% | -67.7% | +5.4% |
| Gross margin | 99.6% | 74.5% (computed) | 77.6% | n/a |
| Operating margin | n/m | n/m | n/m | n/m |
| Net margin | n/m | n/m | n/m | n/m |
| Net income | -$11.90M | -$69.90M | -$14.03M | -$18.63M |
| EPS (Diluted) | -$0.66 | -$5.73 | -$16.56 | -$8.88 |
| Operating cash flow | -$10.45M | -$57.62M | -$9.68M | -$16.19M |
| Free cash flow | -$10.48M | -$57.62M | n/a | -$16.21M |
| Cash & equivalents | n/a | $28.41M | n/a | $1.11M |
| Total assets | $4.18M | $44.92M | $24.93M | $2.60M |
| Total liabilities | $1.57M | $140.38M | $9.16M | $5.08M |
| Shareholders' equity | $2.99M | -$95.46M | $15.76M | -$2.49M |
| Return on year-end equity | -398.1% | n/a | -89.0% | n/a |
| Shares outstanding | 19.56M | 22.33M | 1.56M | 2.68M |
Revenue, most recent five fiscal years
| Fiscal year | Lexaria Bioscience Corp. | BioXcel Therapeutics, Inc. | Onconetix, Inc. | Vaccinex, Inc. |
|---|---|---|---|---|
| Latest | $705.9K Ended 2025-08-31 | $642.0K Ended 2025-12-31 | $815.4K Ended 2025-12-31 | $601.0K Ended 2024-12-31 |
| 1 year earlier | $464.3K Ended 2024-08-31 | $2.27M Ended 2024-12-31 | $2.52M Ended 2024-12-31 | $570.0K Ended 2023-12-31 |
| 2 years earlier | $226.2K Ended 2023-08-31 | $1.38M Ended 2023-12-31 | $58.5K Ended 2023-12-31 | $275.0K Ended 2022-12-31 |
| 3 years earlier | $255.4K Ended 2022-08-31 | $375.0K Ended 2022-12-31 | n/a | $900.0K Ended 2021-12-31 |
| 4 years earlier | $722.7K Ended 2021-08-31 | n/a | n/a | $625.0K Ended 2020-12-31 |